Patients were randomly assigned to a control group receiving placebo ( n = 15 ) , two groups receiving orally administered rosuvastatin ( 10 and 20mg/daily for 30 days ; n = 16 for each group ) , a group receiving BPF alone orally ( 1000 mg/daily for 30 days ; n = 15 ) and a group receiving BPF ( 1000 mg/daily given orally ) plus rosuvastatin ( 10mg/daily for 30 days ; n = 15 ) .